Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials
Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials
复制标题
DOI:
10.1021/jm900743c
复制
发表时间:
2010-03-11
影响因子:
7.3
通讯作者:
Perrone, Roberto
中科院分区:
文献类型:
--
作者:
Colabufo, Nicola Antonio;Berardi, Francesco;Perrone, Roberto
Human ATP binding cassette (ABCa) transporters belong to a family of 49 genes classified into seven subfamilies: ABCA, ABC-B, ABC-C, ABC-D, ABC-E, ABC-F, ABC-G. 1, 2 Some of these transporters are involved in multidrug resistance (MDR), in particular ABC-B1, better known as P-glycoprotein (P-gp), ABC-G2, better known as breast cancer resistance protein (BCRP), and ABC-C1-6, also known as multidrug resistance associated proteins (MRP1-6). 3 These transporters are overexpressed in several tumor cell lines and are responsible for drug efflux out of the cells. 4, 5 They use the energy of ATP hydrolysis to extrude compounds by a complex translocation process. 6 Three models for P-gp translocation have been suggested:(1) pore,(2) flippase, and (3) hydrophobic vacuum cleaner models. 7, 8 In the pore model, drugs binding P-gp to the cytosol are transported out through a protein channel. In the flippase model, P-gp flips drugs that are transported from the inner to the outer compartment of the plasma membrane against a concentration gradient. In the hydrophobic vacuum cleaner model, molecules recognized byP-gp in the lipid bilayer enter the protein from the membranous site and exit through the central cavity. P-gp contains 12 transmembrane helices organized in two membrane spanning domains (MSDs), each containing six transmembrane helices, and two nucleotide binding domains (NBDs) responsible for ATP binding. BCRP is a “half transporter” because it is formed by only one MSD and one NBD although it dimerizes to be fully active. MRPs differ from P-gp because they display three MSDs, and the additional domain contains five transmembrane domains. 3 This review will focus on the physiological and pathological role of P-gp and will highlight the involvement of this protein both in MDR of tumors and in the physiological function of several barriers.